EP Patent

EP1951274B1 — Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Assigned to Aicuris GmbH and Co KG · Expires 2009-12-02 · 16y expired

What this patent protects

Patent listed against neratinib-maleate.

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: EP1951274B1
Jurisdiction: EP
Classification: —
Expires: 2009-12-02
Drug substance claim: No
Drug product claim: No
Assignee: Aicuris GmbH and Co KG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.